Antimicrobial Resistance (AMR)
Antimicrobial Resistance
The
introduction of antimicrobials transformed human and animal health systems by
revolutionizing our weaponry in the war against infectious diseases, resulting
in improved survivability for both humans and their domestic animals. However,
this health triumph was immediately ebbed by the subsequent realization that
bacterial populations could quickly modify themselves to resist antimicrobials,
propagate these resistance traits, and even share resistance genes with other
contemporary bacteria within their environment. Such abilities have seriously
compromised the usefulness of antibiotics in the war against microbes and warn
of a future when antimicrobials may have very limited usefulness to control
bacterial infection Antimicrobial resistance is the ability of a microorganism
to survive and multiply in the presence of an antimicrobial agent that would
normally inhibit or kill this particular kind of organism. Antimicrobial
resistance is just one of the many adaptive traits that resilient bacterial
subpopulations may possess or acquire, enabling them to out-compete and
out-survive their microbial neighbors and overcome host strategies aimed
against them. This phenomenon is nearly as old as the discovery of
antimicrobials themselves, having been described by pioneers like Ehrlich for
trypanosomes8 and Fleming for staphylococci10. What is most alarming today is
the rate at which antibiotic resistance often develops and how quickly it
spreads across the globe and among different species of bacteria. Furthermore,
as a result of sequential, cumulative acquisition of resistance traits against
different antibiotics, more bacterial pathogens with multiple-drug resistance
are being reported worldwide. As a consequence, many bacterial organisms,
including major human and animal pathogens such as Mycobacterium and Salmonella
species, have become resistant to antibiotics which were previously quite
efficacious
Bacterial Resistance Strategies
To
survive in the presence of an antibiotic, bacterial organisms must be able to
disrupt one or more of the essential steps required for the effective action of
the antimicrobial agent.
The
intended modes of action of antibiotics may be counter-acted by bacterial
organisms via several different means. This may involve preventing antibiotic
access into the bacterial cell or perhaps removal or even degradation of the
active component of the antimicrobial agent. No single mechanism of resistance
is considered responsible for the observed resistance in a bacterial organism.
In fact, several different mechanisms may work together to confer resistance to
a single antimicrobial agent.
Four major bacterial resistance
strategies:
(1) By
prevention of the antimicrobial from reaching its target by reducing its ability
to penetrate into the cell
(2) By
expulsion of the antimicrobial agents from the cell via general or specific
efflux pumps
(3) By
inactivation of antimicrobial agents via modification or degradation
(4) By
modification of the antimicrobial target within the bacteria
(1) By
prevention of the antimicrobial from reaching its target by reducing its
ability to penetrate into the cell
Antimicrobial
compounds almost always require access into the bacterial cell to reach their
target site where they can interfere with the normal function of the bacterial
organism. Porin channels are the passageways by which these antibiotics would
normally cross the bacterial outer membrane. Some bacteria protect themselves
by prohibiting these antimicrobial compounds from entering past their cell
walls. For example, a variety of Gram-negative bacteria reduce the uptake of
certain antibiotics, such as aminoglycosides and beta lactams, by modifying the
cell membrane porin channel frequency, size, and selectivity. Prohibiting entry
in this manner will prevent these antimicrobials from reaching their intended
targets that, for aminoglycosides and beta lactams, are the ribosomes and the
penicillin-binding proteins (PBPs), respectively.
This strategy have been
observed in:
Pseudomonas
aeruginosa against imipenem (a beta-lactam antibiotic)
Enterobacter
aerogenes and Klebsiella spp. against imipenem
Vancomycin
intermediate-resistant S. aureus or VISA strains with thickened cell wall
trapping vancomycin
Many
Gram-negative bacteria against aminoglycosides
Many
Gram-negative bacteria against quinolones
(2) By
expulsion of the antimicrobial agents from the cell via general or specific
efflux pumps
To be
effective, antimicrobial agents must also be present at a sufficiently high
concentration within the bacterial cell. Some bacteria possess membrane
proteins that act as an export or efflux pump for certain antimicrobials,
extruding the antibiotic out of the cell as fast as it can enter. This results
in low intracellular concentrations that are insufficient to elicit an effect.
Some efflux pumps selectively extrude specific antibiotics such as macrolides,
lincosamides, streptogramins and tetracyclines, whereas others (referred to as
multiple drug resistance pumps) expel a variety of structurally diverse
anti-infectives with different modes of action. This strategy has been observed
in:
E.coli
and other Enterobacteriaceae against tetracyclines
Enterobacteriaceae
against chloramphenicol
Staphylococci
against macrolides and streptogramins
Staphylococcus
aureus and Streptococcus pneumoniae against fluoroquinolones
(3) By
inactivation of antimicrobial agents via modification or degradation
Another
means by which bacteria preserve themselves is by destroying the active
component of the antimicrobial agent. A classic example is the hydrolytic
deactivation of the beta-lactam ring in penicillins and cephalosporins by the
bacterial enzyme called beta lactamase. The inactivated penicilloic acid will
then be ineffective in binding to PBPs (penicllin binding proteins), thereby
protecting the process of cell wall synthesis. This strategy has also been
observed in:
Enterobacteriaceae
against chloramphenicol (acetylation)
Gram
negative and Gram positive bacteria against aminoglycosides (phosphorylation,
adenylation, and acetylation)
(4) By modification of the
antimicrobial target within the bacteria
Some
resistant bacteria evade antimicrobials by reprogramming or camouflaging
critical target sites to avoid recognition. Therefore, in spite of the presence
of an intact and active antimicrobial compound, no subsequent binding or
inhibition will take place. This strategy has been observed in:
Staphylococci
against methicillin and other beta-lactams (Changes or acquisition of different
PBPs that do not sufficiently bind beta-lactams to inhibit cell wall
synthesis.)
Enterococci
against vancomycin (alteration in cell wall precursor components to decrease
binding of vancomycin)
Mycobacterium
spp. against streptomycin (modification of ribosomal proteins or of 16s rRNA)
Mutations
in RNA polymerase resulting in resistance to the rifamycins;
Mutations
in DNA gyrase resulting in resistance to quinolones
Some Examples Of Bacterial
Resistance Due To Target Site Modification:
Alteration
in penicillin-binding protein (PBPs) leading to reduced affinity of beta-lactam
antibiotics (Methicillin-Resistant Staphylococcus aureus, S. pneumoniae,
Neisseria gonorrheae, Group A streptococci, Listeria monocytogenes)
Changes
in peptidoglycan layer and cell wall thickness resulting to reduced activity of
vancomycin: Vancomycin-resistant S. aureus
Changes
in vancomycin precursors reducing activity of vancomycin: Enterococcus faecium
and E. faecalis
Alterations
in subunits of DNA gyrase reducing activity of fluoroquinolones:
Many
Gram-negative bacteria
Alteration
in subunits of topoisomerase IV leading to reduced activity of
fluoroquinolones: Many Gram positive bacteria, particularly S.auerus and
Streptococcus pneumoniae
Changes
in RNA polymerase leading to reduced activity of rifampicin: Mycobacterium
tuberculosis
Mechanisms
of Resistance Against Different Antimicrobial Classes
ANTIMICROBIAL
CLASS
|
MECHANISM
OF RESISTANCE
|
SPECIFIC
MEANS TO
ACHIEVE
RESISTANCE
|
EXAMPLES
|
Beta-lactams
Examples: penicillin,
ampicillin, mezlocillin, peperacillin, cefazolin, cefotaxime, ceftazidime,
aztreonam, imipenem
|
Enzymatic destruction
|
Destruction of beta-lactam
rings by beta-lactamase enzymes. With the beta-lactam ring destroyed, the
antibiotic will no longer have the ability to bind to PBP (Penicillin-binding
protein), and interfere with cell wall synthesis.
|
Resistance of staphylococi to
penicillin;
Resistance of
Enterobacteriaceae to penicllins, cephalosporins, and aztreonam
|
Altered target
|
Changes in penicillin binding
proteins. Mutational changes in original PBPs or acquisition of different
PBPs will lead to inability of the antibiotic to bind to the PBP and inhibit
cell wall synthesis
|
Resistance of staphylococci
to methicillin and oxacillin
|
|
Decreased uptake
|
Porin channel formation is
decreased. Since this is where beta-lactams cross the outer membrane to reach
the PBP of Gram-negative bacteria, a change in the number or character of
these channels can reduce betalactam uptake..
|
Resistance of Enterobacter
aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa to imipenem
|
|
Glycopeptides
Example: vancomycin
|
Altered target
|
Alteration in the molecular
structure of cell wall precursor components decreases binding of vancomycin
so that cell wall synthesis is able to continue.
|
Resistance of enterococci to
vancomycin
|
Aminoglyosides
Examples: gentamicin,
tobramycin, amikacin, netilmicin, streptomycin, kanamycin
|
Enzymatic modification
|
Modifying enzymes alter
various sites on the aminoglycoside molecule so that the ability of this drug
to bind the ribosome and halt protein synthesis is greatly diminished or lost
entirely.
|
Resistance of many
Gram-positive and Gram negative bacteria to aminoglycosides
|
Decreased uptake
|
Change in number or character
of porin channels (through which aminoglycosides cross the outer membrane to
reach the ribosomes of gram-negative bacteria) so that aminoglycoside uptake
is diminished.
|
Resistance of a variety of
Gram-negative bacteria to aminoglycosides
|
|
Altered target
|
Modification of ribosomal
proteins or of 16s rRNA. This reduces the ability of aminoglycoside to
successfully bind and inhibit protein synthesis
|
Resistance of Mycobacterium
spp to streptomycin
|
|
Quinolones
Examples: ciprofloxacin,
levofloxacin, norfloxacin, lomefloxacin
|
Decreased uptake
|
Alterations in the outer
membrane diminishes uptake of drug and/or activation of an “efflux” pump that
removes quinolones before intracellular concentration is sufficient for
inhibiting DNA metabolism.
|
Resistance of Gram negative
and staphylococci (efflux mechanism only) to various quinolones
|
Altered target
|
Changes in DNA gyrase
subunits decrease the ability of quinolones to bind this enzyme and interfere
with DNA processes
|
Gram negative and Gram
positive resistance to
|
ANTIBIOTIC MODES OF ACTION AND BACTERIAL
MECHANISMS OF RESISTANCE
Molecular mechanisms of
resistance
The
abilities of bacterial organisms to utilize the various strategies to resist
antimicrobial compounds are all genetically encoded.
Intrinsic
resistance is that type of resistance which is naturally coded and expressed by
all (or almost all) strains of that particular bacterial species. An example of
instrinsic resistance is the natural resistance of anaerobes to aminoglycosides
and Gram-negative bacteria against vancomycin. Changes in bacterial genome
through mutation or horizontal gene acquisition, on the other hand, may
consequently lead to a change in the nature of proteins expressed by the
organism. Such change may lead to an alteration in the structural and
functional features of the bacteria involved, which may result in changes
leading to resistance against a particular antibiotic. This is referred to as
acquired resistance, which is limited to selected isolates of that particular
species or group of microorganisms. For example, we know that methicillin
resistance of Staphylococcus aureus is primarily due to changes that occur in
the penicillin binding protein (PBP), which is the protein which beta-lactam
antibiotics bind and inactivate to consequently inhibit cell wall synthesis.
This change is actually rendered by the expression of a certain mecA gene in
some strains of these bacteria, which is hypothesized to have been induced by
the excessive use of penicillin. Expression of this mecA gene results in an
alternative PBP (PBP2a) that has a low affinity for most ß-lactam antibiotics,
thereby allowing these strains to replicate in the presence of methicillin and
related antibiotics. Some antimicrobial resistance is brought about by multiple
changes in the bacterial genome. For example, Isoniazid resistance of
Mycobacterium tuberculosis results from changes in the following genes: katG
gene which encodes a catalase; inhA gene which is the target for isoniazid; the
oxyR gene and neighboring aphC gene and their intergenic region.
Biological
Versus Clinical Resistance Biological resistance refers to changes that result
in the organism being less susceptible to a particular antimicrobial agent than
has been previously observed. When antimicrobial susceptibility has been lost
to such an extent that the drug is no longer effective for clinical use, the
organism is then said to have achieved clinical resistance. It is important to
note that often, biologic resistance and clinical resistance do not necessarily
coincide. From a clinical laboratory and public health perspective it is
important to realize that biologic development of antimicrobial resistance is
an ongoing process, while clinical resistance is dependent on current laboratory
methods and established cut-offs. Our inability to reliably detect all these
processes with current laboratory procedures and criteria should not be
perceived as evidence that they are not occurring.
Intrinsic Resistance
Intrinsic
resistance is the innate ability of a bacterial species to resist activity of a
particular antimicrobial agent through its inherent structural or functional
characteristics, which allow tolerance of a particular drug or antimicrobial
class. This can also be called “insensitivity” since it occurs in organisms
that have never been susceptible to that particular drug. Such natural
insensitivity can be due to:
lack of
affinity of the drug for the bacterial target
inaccessibility
of the drug into the bacterial cell
extrusion
of the drug by chromosomally encoded active exporters
innate
production of enzymes that inactivate the drug
Examples
of intrinsic resistance and their respective mechanisms
ORGANISMS
|
NATURAL
RESISTANCE AGAINST:
|
MECHANISM
|
||
Anaerobic bacteria
|
Aminoglycosides
|
Lack of oxidative metabolism
to drive uptake of aminoglycosides
|
||
Aerobic bacteria
|
Metronidazole
|
Inability to anaerobically
reduce drug to its active form
|
||
Gram-positive bacteria
|
Aztreonam (a beta-lactam)
|
Lack of penicillin binding
proteins (PBPs) that bind and are inhibited by this beta lactam antibiotic
|
||
Gram-negative bacteria
|
Vancomycin
|
Lack of uptake resulting from
inability of vancomycin to penetrate outer membrane
|
||
Klebsiella spp.
|
Ampicillin (a beta-lactam)
|
Production of enzymes
(beta-lactamases) that destroy ampicillin before the drug can reach the PBP
targets
|
||
Stenotrophomonas. maltophila
|
Imipenem (a beta-lactam)
|
Production of enzymes (beta
lactamases) that destroy imipenem before the drug can reach the PBP targets.
|
||
Lactobacilli and Leuconostoc
|
Vancomycin
|
Lack of appropriate cell wall
precursor target to allow vancomycin to bind and inhibit cell wall synthesis
|
||
Pseudomonas aeruginosa
|
Sulfonamides, trimethoprim,
tetracycline, or chloramphenicol
|
Lack of uptake resulting from
inability of antibiotics to achieve effective intracellular concentrations
|
||
Enterococci
|
Aminoglycosides
|
Lack of sufficient oxidative
metabolism to drive uptake of aminoglycosides
|
||
|
All cephalosporins
|
Lack of PBPs that effectively
bind and are inhibited by these beta lactam antibiotics
|
||
Clinical
implications: Intrinsic Resistance Knowledge of the intrinsic resistance of a
pathogen of concern is important in practice to avoid inappropriate and
ineffective therapies. For bacterial pathogens which are naturally insensitive
to a large number of classes of antimicrobials, such as Mycobacterium
tuberculosis and Pseudomonas aeruginosa, this consideration can pose a
limitation in the range of options for treatment and thus consequently further
increase the risk for emergence of acquired resistance.
Acquired Resistance
Acquired
resistance is said to occur when a particular microorganism obtains the ability
to resist the activity of a particular antimicrobial agent to which it was
previously susceptible. This can result from the mutation of genes involved in
normal physiological processes and cellular structures, from the acquisition of
foreign resistance genes or from a combination of these two mechanisms. Unlike
intrinsic resistance, traits associated with acquired resistance are found only
in some strains or subpopulations of each particular bacterial species.
Laboratory methods are therefore needed to detect acquired resistance in
bacterial species that are not intrinsically resistant. These same methods are
used for monitoring rates of acquired resistance as a means of combating the
emergence and spread of acquired resistance traits in pathogenic and
non-pathogenic bacterial species. Acquired resistance results from successful
gene change and/or exchange that may involve: mutation or horizontal gene
transfer via transformation, transduction or conjugation.
Examples
of acquired resistance through mutation and horizontal gene transfer
ACQUIRED
RESISTANCE THROUGH:
|
RESISTANCE
OBSERVED
|
MECHANISM
INVOLVED
|
|
Mutations
|
Mycobacterium tuberculosis
resistance to rifamycins
|
Point mutations in the
rifampin-binding region of rpoB
|
|
|
Resistance of many clinical
isolates to luoroquinolones
|
Predominantly mutation of the
quinolone-resistance-determining-regiont (QRDR) of GyrA and ParC/GrlA
|
|
|
E.coli, Hemophilius
influenzae resistance to trimethoprim
|
Mutations in the chromosomal
gene specifying dihydrofolate reductase
|
|
Horizontal gene transfer
|
Staphylococcus aureus
resistance to methicillin (MRSA)
|
Via acquisition of mecA genes
which is on a mobile genetic element called “staphylococcal cassette
chromosome” (SCCmec) which codes for penicllin binding proteins (PBPs) that
are not sensitive to ß-lactam inhibition
|
|
|
Resistance of many pathogenic
bacteria against sulfonamides
|
Mediated by the horizontal
transfer of foreign folP genes or parts of it
|
|
|
Enterococcus faecium and E.
faecalis resistance to vancomycin
|
Via acquisition of one of two
related gene clusters VanA and Van B, which code for enzymes that modify
peptidoglycan precursor, reducing affinity to vancomycin.
|
|
Antibiotics
exert selective pressure on bacterial populations, killing susceptible bacteria
while allowing strains with resistance to that particular antibiotic to survive
and multiply. Traits for such resistance are then vertically passed on to
daughter cells, subsequently creating a resistant population which can then
spread and be further sources of resistance genes for other strains. Because
resistance traits are not naturally eliminated or reversed, resistance to a
variety of antibiotics may be accumulated over time. This can lead to strains
with multiple drug resistance, which are more difficult to kill due to reduced
treatment options.
Mutation
A
mutation is a spontaneous change in the DNA sequence within the gene that may
lead to a change in the trait which it codes for. Any change in a single base
pair may lead to a corresponding change in one or more of the amino acids for
which it codes, which can then change the enzyme or cell structure that
consequently changes the affinity or effective activity of the targeted
antimicrobials. In prokaryotic genomes, mutations frequently occur due to base
changes caused by exogenous agents, DNA polymerase errors, deletions,
insertions and duplications. For prokaryotes, there is a constant rate of
spontaneous mutation of about 0.0033 mutations per DNA replication that is
relatively uniform for a diverse spectrum of organisms. The mutation rate for
individual genes varies significantly among and within genes (Gillespie, 2002).
Horizontal Gene Transfer
Horizontal
gene transfer, or the process of swapping genetic material between neighboring
“contemporary” bacteria, is another means by which resistance can be acquired.
Many of the antibiotic resistance genes are carried on plasmids, transposons or
integrons that can act as vectors that transfer these genes to other members of
the same bacterial species, as well as to bacteria in another genus or species.
Horizontal gene transfer may occur via three main mechanisms: transformation,
transduction or conjugation.
Transformation
involves uptake of short fragments of naked DNA by naturally transformable
bacteria. Transduction involves transfer of DNA from one bacterium into another
via bacteriophages. Conjugation involves transfer of DNA via sexual pilus and
requires cell –to-cell contact. DNA fragments that contain resistance genes
from resistant donors can then make previously susceptible bacteria express
resistance as coded by these newly acquired resistance genes.
Detecting antimicrobial
resistance
Historically,
veterinary practitioners prescribed antibiotics based on expected mode of
action, spectrum of activity and clinical experience. With the emergence and
spread of antimicrobial resistance, treatment of bacterial infections has become
increasingly difficult and is no longer as straightforward as it was many years
prior. Practitioners now need to consider that the particular pathogen they
wish to treat may be resistant to some or all of the available antibiotics,
thus making antimicrobial susceptibility testing a standard procedure.
Antimicrobial susceptibility testing methods are in vitro procedures used to
detect antimicrobial resistance in individual bacterial isolates. Because these
laboratory detection methods can determine resistance or susceptibility of an
isolate against an array of possible therapeutic candidates, antimicrobial
susceptibility testing results can be a useful clinical guideline in selecting
the best antibiotic treatment option for each particular patient. These same
methods can also be used for monitoring the emergence and spread of resistant
microorganisms in the population. Clinical Breakpoints are threshold values
established for each pathogen-antibiotic (i.e., bug-drug) combination
indicating at what level of antibiotic the isolate should be considered to be
sensitive, intermediate or resistant. The interpretative criteria for these are
based on extensive studies that correlate laboratory resistance data with serum
achievable levels for each antimicrobial agent and a history of successful and
unsuccessful therapeutic outcomes. Although veterinary laboratories originally
based interpretations on standards established using human pathogens, it became
apparent by the early 1980s that such an approach did not reliably predict
clinical outcomes when applied to veterinary practrice. Subsequently, groups
within organizations that set standards were created for the purpose of
developing veterinary-specific standards28. Standard conditions for these
assays have been established based on extensive batteries of laboratory
testing. Guidelines and recommendations for these are continuously updated by
certain organizations worldwide, such as CLSI, EUCAST, OIE, BSAC, SFM, SRGA and
CDS. Of these, those which specify antimicrobial testing methods and
interpretative criteria for veterinary pathogens are: the CLSI in the USA, OIE
in EU and CDS-AST in Australia.
Lab approaches and strategies
Some
points to consider when deciding whether or not to conduct antimicrobial
susceptibility testing should include:
clinical
relevance of the isolate
purity
of the isolate
logical
panel of antimicrobial agents to be tested (i.e., do not include antibiotics to
which the isolate is known to have intrinsic resistance)
availability
of test methodology, resources, and trained personnel
standardization
of testing
valid
interpretation of results
cost
efficiency
effective
means to communicate results and interpretation to end-users
Most
often, interpretation is reduced to whether the isolate is classified as
susceptible, intermediately susceptible, or resistant to a particular
antibiotic.. It should, however, be remembered that these in vitro procedures
are only approximations of in vivo conditions which can be very different
depending on the nature of the drug, the nature of the host and the conditions
surrounding the interaction between the antibiotic and the target pathogen. One
critical aspect is following standardized procedures that can generate
reproducible results, i.e. quality control. Aspects of quality control include:
standardized
bacterial inoculum size
culture
conditions (growth medium, pH, cation concentration
blood
and serum supplements and thymidine content)
incubation
conditions (atmosphere, temperature, duration)
concentration
of antimicrobials for testing.
Because
of the required culture time, antimicrobial susceptibility testing may take
several days, which is not ideal particularly in critical clinical cases
demanding urgency. Often, practitioners may utilize locally established
antibiograms as guideline for therapy. An antibiogram is a compiled susceptibility
report or table of commonly isolated organisms in a particular hospital, farm,
or geographic area, which can serve as a useful guideline in therapy before
actual culture and susceptibility data becomes available for reference.
Test Methods in Detecting
Antimicrobial Resistance
There
are several antimicrobial susceptibility testing methods available today, and
each one has their respective advantages and disadvantages. They all have one
and the same goal, which is to provide a reliable prediction of whether an
infection caused by a bacterial isolate will respond therapeutically to a
particular antibiotict reatment. This data may be utilized as guidelines for
chemotherapy, or at the population level as indicators of emergence and spread
of resistance based on passive or active surveillance. Some examples of
antibiotic sensitivity tesing methods are:
Dilution
method (broth and agar dilution method)
Disk-diffusion
method
E-test
Automated
methods
Mechanism-specific
tests such as beta-lactamase detection test and chromogenic cephalosporin test
Genotypic
methods such as PCR and DNA hybridization methods
Selection
of the appropriate method will depend on the intended degree of accuracy,
convenience, urgency, availability of resources, availability of technical
expertise and cost.. Interpretation should be based on veterinary standards
whenever possible, rather than on human medical standards, which may not always
be applicable. Among these available tests, the two most commonly used methods
in veterinary laboratories are the agar disk-diffusion method and the broth
microdilution method.
Examples of Antibiotic
Sensitivity Testing Methods
On this
agar plate, a bacterial isolate is tested for resistance to each of twelve
different antibiotics. The clear zones around each disc are the zones of
inhibition that indicate the extent of the test organism’s inability to survive
in the presence of the test antibiotic. (A)The disk shows a large zone of
inhibition; whereas (B) shows no zone of inhibition, indicating resistance of
the isolate to the test antibiotic Presence of zone of inhibition is not
automatically interpreted as susceptibility to the antibiotic; the zone width
has to be measured and compared against a reference standard which contains
measurement ranges and their equivalent qualitative categories of susceptible,
intermediately susceptible or resistant.
For
example, this E.coli isolate on the right has a zone of inhibition of 10.1mm around
ampicillin (AM); since the zone diameter interpretation chart is as follows:
Resistant:
13mm or less
Intermediate:
14-16 mm
Susceptible:
17 mm or more
This particular E.coli isolate
is read as resistant to ampicillin.
1. DILUTION METHODS
The
Broth dilution method involves subjecting the isolate to a series of
concentrations of antimicrobial agents in a broth environment. Microdilution
testing uses about 0.05 to 0.1 ml total broth volume and can be conveniently
performed in a microtiter format. Macrodilution testing uses broth volumes at
about 1.0 ml in standard test tubes. For both of these broth dilution methods,
the lowest concentration at which the isolate is completely inhibited (as
evidenced by the absence of visible bacterial growth) is recorded as the
minimal inhibitory concentration or MIC. The MIC is thus the minumum
concentration of the antibiotic that will inhibit this particular isolate. The
test is only valid if the positive control shows growth and the negative
control shows no growth. A procedure similar to broth dilution is agar
dilution. Agar dilution method follows the principle of establishing the lowest
concentration of the serially diluted antibiotic concentration at which
bacterial growth is still inhibited.
2. DISK DIFFUSION METHOD
Because
of convenience, efficiency and cost, the disk diffusion method is probably the
most widely used method for determining antimicrobial resistance in private
veterinary clinics. A growth medium, usually Mueller-Hinton agar, is first evenly
seeded throughout the plate with the isolate of interest that has been diluted
at a standard concentration (approximately 1 to 2 x 108 colony forming units
per ml). Commercially prepared disks, each of which are pre-impregnated with a
standard concentration of a particular antibiotic, are then evenly dispensed
and lightly pressed onto the agar surface. The test antibiotic immediately
begins to diffuse outward from the disks, creating a gradient of antibiotic
concentration in the agar such that the highest concentration is found close to
the disk with decreasing concentrations further away from the disk. After an
overnight incubation, the bacterial growth around each disc is observed. If the
test isolate is susceptible to a particular antibiotic, a clear area of “no
growth” will be observed around that particular disk. The zone around an
antibiotic disk that has no growth is referred to as the zone of inhibition
since this approximates the minimum antibiotic concentration sufficient to
prevent growth of the test isolate. This zone is then measured in mm and
compared to a standard interpretation chart used to categorize the isolate as
susceptible, intermediately susceptible or resistant. MIC measurement cannot be
determined from this qualitative test, which simply classifies the isolate as
susceptible, intermediate or resistant.
3.
E-TEST
E-test
(AB Biodisk, Solna, Sweden) is a commercially available test that utilizes a
plastic test strip impregnated with a gradually decreasing concentration of a
particular antibiotic. The strip also displays a numerical scale that
corresponds to the antibiotic concentration contained therein. This method
provides for a convenient quantitative test of antibiotic resistance of a
clinical isolate. However, a separate strip is needed for each antibiotic, and
therefore the cost of this method can be high.
4. AUTOMATED ANTIMICROBIAL
SUSCEPTIBILITY TESTING SYSTEMS
Several
commercial systems have been developed that provide conveniently prepared and
formatted microdilution panels as well as instrumentation and automated reading
of plates. These methods are intended to reduce technical errors and lengthy
preparation times. Most automated antimicrobial susceptibility testing systems
provide automated inoculation, reading and interpretation. These systems have
the advantage of being rapid (some results can be generated within hours) and
convenient, but one major limitation for most laboratories is the cost entailed
in initial purchase, operation and maintenance of the machinery. Some examples
of these include: Vitek System (bioMerieux, France), Walk-Away System (Dade
International, Sacramento, Calif.), Sensititre ARIS (Trek Diagnostic Systems,
East Grinstead, UK), Avantage Test System (Abbott Laboratories, Irving, Texas),
Micronaut (Merlin, Bornheim-Hesel, Germany), Phoenix (BD Biosciences, Maryland)
and many more.
5. MECHANISM-SPECIFIC TESTS
Resistance
may also be established through tests that directly detect the presence of a
particular resistance mechanism. For example, beta lactamase detection can be
accomplished using an assay such as the chromogenic cephalosporinase test
(Cefinase disk by BD Microbiology Systems, Cockeysville, MD and BBL DrySlide
Nitrocefin, Becton Dickinson, Sparks, MD) and detection for chloramphenicol
modifying enzyme chloramphenicol acetyltransferase (CAT) may utilize commercial
colorimetric assays such as a CAT reagent kit (Remel, Lenexa, Kansas).
6. GENOTYPIC METHODS
Since
resistance traits are genetically encoded, we can sometimes test for the
specific genes that confer antibiotic resistance. However, although nucleic
acid-based detections systems are generally rapid and sensitive, it is
important to remember that the presence of a resistance gene does not
necessarily equate to treatment failure, because resistance is also dependent
on the mode and level of expression of these genes11. Some of the most common
molecular techniques utilized for antimicrobial resistance detection are as
follows:
Polymerase
chain reaction (PCR) is one of the most commonly used molecular techniques for
detecting certain DNA sequences of interest. This involves several cycles of
denaturation of sample DNA, annealing of specific primers to the target
sequence (if present), and the extension of this sequence as facilitated by a thermostable
polymerase leading to replication of a duplicate DNA sequence, in an
exponential manner, to a point which will be visibly detectable by gel
electrophoresis with the aid of a DNA-intercalating chemical which fluoresces
under UV light.
DNA
hybridization. This is based on the fact that the DNA pyrimidines (cytosine and
thymidine) specifically pair up with purines (guanine and adenine; or uracil
for RNA). Therefore, a labeled probe with a known specific sequence can pair up
with opened or denatured DNA from the test sample, as long as their sequences
complement each other. If this “hybridization” occurs, the probe labels this
with a detectable radioactive isotope, antigenic substrate, enzyme or
chemiluminescent compound. Whereas if no target sequence is present or the
isolate does not have the specific gene of interest, no attachment of probes
will occur, and therefore no signals will be detected.
Modifications
of PCR and DNA hybridization. With these basic principles, several
modifications have been introduced which further improve the sensitivity and
specificity of these standard procedures. Examples of such development were the
use of 5’-fluorescence-labeled oligonucleotides, the development of molecular
beacons, development of DNA arrays and DNA chips, among many others.
Comments
Post a Comment